New drugs under development against obesity show weight reductions of up to 22 percent of body weight after 48 weeks of treatment. The drug retatrutide, which combines three appetite-regulating hormones, shows the best results so far in clinical trials.
GLP-1 drugs like Ozempic and Wegovy reduce the risk of heart attacks and strokes by 20 percent in overweight people with cardiovascular disease. The drugs could save countries $429 billion annually between 2020-2060 if obesity increase slows by 5 percent.
Obesity among adults in the USA is 40.3 percent according to a new report. This is a decrease from 41.9 percent in 2020. It breaks a trend of annual increases that has been ongoing since 2011.